{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "Arunachalam_et_al.__2021_",
  "verification_stats": {
    "total_extracted": 6,
    "verified": 5,
    "rejected": 1,
    "verification_rate": 0.8333333333333334
  },
  "verified_evidence": [
    {
      "id": 1,
      "quote": "Recently Richards et al.65 examined CD4 T-cell and antibody responses in healthy adults who received egg derived split vaccine, cell derived split vaccine or RIV4 for three successive influenza seasons (2015-2016, 2016-2017, and 2017-2018 65. RIV4 elicited the most robust responses, with significantly higher T-cell and antibody levels than the other two vaccines. Authors postulated that simpler glycosylation of rHA and absence of other influenza viral proteins in RIV4 contributed to the observed robust immune response for RIV4 and emphasised the relevance of these features in determining vaccine efficacy and long term immunity 65.",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It reports that RIV4 (a higher-dose recombinant flu vaccine) elicited 'significantly higher T-cell and antibody levels' than both egg-derived and cell-derived split vaccines in healthy adults over three influenza seasons. This is a direct comparison of antibody responses, showing that the recombinant vaccine induced a more robust response than standard egg-based vaccines, which is exactly what the claim asserts.",
      "presence_explanation": "The quote appears on page 5 of the document, with only minor differences in wording and formatting. The factual content is preserved: 'Recently Richards et al.65 examined CD4 T-cell and antibody responses in healthy adults who received egg derived split vaccine, cell derived split vaccine or RIV4 for three successive influenza seasons (2015-2016, 2016-2017, and 2017-2018 65. RIV4 elicited the most robust responses, with significantly higher T-cell and antibody levels than the other two vaccines. Authors postulated that simpler glycosylation of rHA and absence of other influenza viral proteins in RIV4 contributed to the observed robust immune response for RIV4 and emphasised the relevance of these features in determining vaccine efficacy and long term immunity 65.' The quote in the prompt is a cleaned and slightly reformatted version of the text found in the document, but all technical content, numbers, and claims are present and accurate.",
      "support_explanation": "The quote directly supports the claim. It reports that RIV4 (a higher-dose recombinant flu vaccine) elicited 'significantly higher T-cell and antibody levels' than both egg-derived and cell-derived split vaccines in healthy adults over three influenza seasons. This is a direct comparison of antibody responses, showing that the recombinant vaccine induced a more robust response than standard egg-based vaccines, which is exactly what the claim asserts.",
      "original_relevance": "This quote directly compares the antibody responses induced by the higher-dose recombinant vaccine (RIV4) and standard egg-based vaccines, showing that RIV4 produced significantly higher antibody levels, supporting the claim."
    },
    {
      "id": 2,
      "quote": "Portnoff et al.64 demonstrated that recombinant HA antigens (specifically for the H3 strain) produced using BEVS (as used for RIV4), induced significantly higher levels of broadly cross reactive antibodies against highly conserved regions of the HA head and stem domains than egg derived split vaccines 64.",
      "supports_claim": true,
      "explanation": "The quote directly compares recombinant HA antigens (as used in RIV4, a higher-dose recombinant flu vaccine) to egg-derived split vaccines (standard-dose, egg-based vaccines), stating that the recombinant vaccine induced 'significantly higher levels of broadly cross reactive antibodies.' This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "The quote appears on page 5 of the document: 'Portnoff et al.64 demonstrated that recombinant HA antigens (specifically for the H3 strain) produced using BEVS (as used for RIV4), induced significantly higher levels of broadly cross reactive antibodies against highly conserved regions of the HA head and stem domains than egg derived split vaccines 64.' The wording and factual content match the quote to verify, with only minor formatting differences (e.g., line breaks, punctuation) but all technical content and meaning are preserved.",
      "support_explanation": "The quote directly compares recombinant HA antigens (as used in RIV4, a higher-dose recombinant flu vaccine) to egg-derived split vaccines (standard-dose, egg-based vaccines), stating that the recombinant vaccine induced 'significantly higher levels of broadly cross reactive antibodies.' This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote provides evidence that the recombinant vaccine (RIV4) induces higher levels of antibodies than egg-based standard-dose vaccines, supporting the claim of a more robust antibody response."
    },
    {
      "id": 3,
      "quote": "Higher magnitudes of haem agglutination inhibitory antibody response against HA1 have also been observed with RIV4 compared to egg- or mammalian cell derived split vaccines (Flucelvax Tetra, Seqirus, and Fluzone quadrivalent SD, Sanofi Pasteur 60.",
      "supports_claim": true,
      "explanation": "The quote directly compares RIV4 (a recombinant quadrivalent influenza vaccine) to both egg-based and mammalian cell-derived standard-dose split vaccines, stating that RIV4 induces higher magnitudes of haemagglutination inhibitory antibody responses against HA1. This is explicit evidence that RIV4 may induce a more robust antibody response than standard-dose egg-based vaccines, thus directly supporting the claim.",
      "presence_explanation": "The quote appears on page 5 of the document, with only minor differences in formatting and punctuation. The document states: 'Higher magnitudes of haem agglutination inhibitory antibody response against HA1 have also been observed with RIV4 compared to egg- or mammalian cell derived split vaccines (Flucelvax Tetra, Seqirus, and Fluzone quadrivalent SD, Sanofi Pasteur 60.' This matches the quoted content in meaning and technical detail.",
      "support_explanation": "The quote directly compares RIV4 (a recombinant quadrivalent influenza vaccine) to both egg-based and mammalian cell-derived standard-dose split vaccines, stating that RIV4 induces higher magnitudes of haemagglutination inhibitory antibody responses against HA1. This is explicit evidence that RIV4 may induce a more robust antibody response than standard-dose egg-based vaccines, thus directly supporting the claim.",
      "original_relevance": "This quote explicitly states that RIV4 (a higher-dose recombinant vaccine) elicits higher antibody responses than standard egg-based vaccines, directly supporting the claim."
    },
    {
      "id": 4,
      "quote": "In a small study by Belongia et al.82, participants aged 65-74 years were immunised with RIV4, a high dose split virion inactivated trivalent influenza vaccine (Fluzone High Dose, Sanofi Pasteur; HD-IIV3) or adjuvanted-IIV3 (aIIV3)82. Participant sera were tested against four A/H3N2 viruses including a cell propagated reference vaccine strain, two circulating viruses and an antigenically advanced virus with evidence of antigenic drift. The post vaccination geometric mean fold rise against the two circulating viruses was twice as high for RIV4 as for HD-IIV3 or aIIV3.",
      "supports_claim": true,
      "explanation": "The quote directly compares the antibody response (measured as geometric mean fold rise) between RIV4 (a higher-dose recombinant flu vaccine) and both high-dose and adjuvanted egg-based vaccines in older adults. It states that the antibody response to two circulating viruses was twice as high for RIV4 as for the egg-based high-dose or adjuvanted vaccines. This provides explicit evidence that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose (and even high-dose) vaccines, thus supporting the claim.",
      "presence_explanation": "The quote appears on page 5 of the document, with only minor differences in formatting and wording. The essential content is preserved: 'In a small study by Belongia et al.82, participants aged 65-74 years were immunised with RIV4, a high dose split virion inactivated trivalent influenza vaccine (Fluzone High Dose, SanofiPasteur; HD-IIV3) or adjuvanted-IIV3 (aIIV3)82. Participant sera were tested against four A/H3N2 viruses including a cell propagated reference vaccine strain, two circulating viruses and an antigenically advanced virus with evidence of antigenic drift. The post vaccination geometric mean fold rise against the two circulating viruses was twice as high for RIV4 as for HD-IIV3 or aIIV3.' The quote in the document is semantically equivalent to the one provided.",
      "support_explanation": "The quote directly compares the antibody response (measured as geometric mean fold rise) between RIV4 (a higher-dose recombinant flu vaccine) and both high-dose and adjuvanted egg-based vaccines in older adults. It states that the antibody response to two circulating viruses was twice as high for RIV4 as for the egg-based high-dose or adjuvanted vaccines. This provides explicit evidence that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose (and even high-dose) vaccines, thus supporting the claim.",
      "original_relevance": "This quote provides direct comparative data showing that RIV4 (a higher-dose recombinant vaccine) induced a greater antibody response than both high-dose and adjuvanted egg-based vaccines, supporting the claim."
    },
    {
      "id": "comp_1",
      "quote": "In a study by Nachbagauer et al.78, RIV4 induced HA stem specific neutralising antibodies directed against influenza subtypes H1, H3 and B haemagglutinin in an age dependent manner in humans, with the highest titres observed in the elderly 78. RIV4 also induces antibodies, in both humans and mice, that are specific to epitopes in the HA head region, at greater proportions than a traditional mammalian cell derived subunit vaccine (Flucelvax [Trivalent] 77.",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It states that RIV4 (a higher-dose recombinant flu vaccine) induces HA stem-specific neutralising antibodies in humans, with the highest titres in the elderly, and that RIV4 induces antibodies to HA head epitopes at greater proportions than a traditional mammalian cell-derived subunit vaccine. This provides direct evidence that RIV4 may induce a more robust antibody response than standard-dose, egg-based (or mammalian cell-based) vaccines, as claimed.",
      "presence_explanation": "The quote appears on page 5 of the document, with only minor differences in wording and formatting. The factual content is preserved: 'In a study by Nach bag auer et al.78, RIV4 induced HA stem specific neutral ising antibodies directed against influenza subtypes H1, H3 and B haem agglutinin in an age dependent manner in humans, with the highest titres observed in the elderly 78. RIV4 also induces antibodies, in both humans and mice, that are specific to epi topes in the HA head region, at greater proportions than a traditional mammalian cell derived subunit vaccine (Flu cel vax [Trivalent 77.' This matches the quote to verify, with only minor differences in spacing and punctuation.",
      "support_explanation": "The quote directly supports the claim. It states that RIV4 (a higher-dose recombinant flu vaccine) induces HA stem-specific neutralising antibodies in humans, with the highest titres in the elderly, and that RIV4 induces antibodies to HA head epitopes at greater proportions than a traditional mammalian cell-derived subunit vaccine. This provides direct evidence that RIV4 may induce a more robust antibody response than standard-dose, egg-based (or mammalian cell-based) vaccines, as claimed.",
      "original_relevance": "This quote provides direct evidence that RIV4 (a higher-dose recombinant flu vaccine) induces higher levels of specific antibodies, including stem-specific neutralising antibodies, compared to a traditional mammalian cell-derived vaccine, supporting the claim of a more robust antibody response."
    }
  ],
  "rejected_evidence": [
    {
      "id": "comp_2",
      "quote": "Subsequent studies showed that HA with simpler glycans induce more broadly protective antibodies with superior cross clade protection compared to HA with more complex glycans76-79. The presence of simpler glycans appears to be equally efficient to that of chicken or mammalian cell derived glycosylation in ensuring the proper folding of HA, and exposes conserved regions of the molecule for the induction of immunity with broader protection 12 71 76 80.",
      "reason": "does not support claim",
      "original_explanation": "This quote supports the claim by stating that recombinant HA (with simpler glycans, as in RIV4) induces more broadly protective antibodies than conventional (egg-based) vaccines, indicating a more robust and broader antibody response."
    }
  ],
  "model_used": "gpt-4.1"
}